Bal Pharma Ltd

Timeline for net proceeds utilization

• 18-month window to utilize net proceeds from the convertible warrants, from allotment date.
• Subject to requisite in-principle approval from stock exchanges.
• No change in objects or manner of utilization of proceeds.
• Regulatory basis: Regulation 162 of SEBI ICDR Regulations 2018.
• Date of filing: August 25, 2026.

Standalone results

• Revenue from operations ₹8,842.73 lakhs; +34.7% YoY.
• Total income ₹8,888.44 lakhs; +34.0% YoY.
• Net profit ₹116.10 lakhs; +258.9% YoY.
• EPS basic and diluted ₹0.73.
• Single reportable segment: Pharmaceuticals.

Consolidated results

• Revenue from operations ₹8,861.61 lakhs; +34.5% YoY.
• Total income ₹8,905.43 lakhs; +33.8% YoY.
• Net profit ₹113.77 lakhs; EPS ₹0.71 (basic and diluted).
• Single reportable segment: Pharmaceuticals.

Financial results approved

• Standalone unaudited results approved for quarter ended 30 June 2026.
• Consolidated unaudited results approved for quarter ended 30 June 2026.
• Auditors SSJNB & Co issued unmodified opinion on results.
• No deviation/variation report required as no funds were raised.

Director designations

• Ravindra Kothari to become Whole-Time Director (Executive) from 1 Oct 2026.
• Virupakshaya Himesh to become Non-Executive Director from 1 Oct 2026.

Philippines JV investment

• Approved investment in Philippines JV up to INR 9 crore within board powers.
• JV ownership Bal Pharma 65%, Hemera 35%.
• Investment to comply with FEMA/ ODI and other regulatory approvals.

Warrant issue and funding

• Allotment of 10,00,000 warrants to promoter Shailesh Siroya at ₹84 per warrant.
• Total amount ₹8.40 crore; 25% received ₹2.10 crore.
• Warrants convertible into one equity share after balance 75% payment within 18 months.
• Subject to applicable regulatory approvals; ISIN and details to be submitted to exchanges.

Regulatory/compliance disclosures

• Declaration of unmodified opinion on audited standalone and consolidated results for quarter ended 30 June 2026.
• Non-applicability of deviation/variation in fund utilization due to no funds raised.

Warrant issue to promoter (special resolution)

• Special resolution: issue of 1,000,000 warrants to promoter on a preferential basis.
• Outcome: Approved by requisite majority; assent 99.96%, dissent 0.04%.
• Voting details: 99 members participated; total votes 8,159,063.

Postal Ballot Result

• Special Resolution 01: issue of 10,00,000 warrants to promoter on preferential basis.
• Result: 99.96% in favour, 0.04% against; passed by requisite majority.
• Counterparty: promoter; related-party transaction; promoter group voted in favour.
• Terms: price and other warrant terms not disclosed in filing.
• No abstentions recorded; promoter votes accounted for 100% of promoter shares.

Meeting Details

• Date: August 12, 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for Q1 FY2026-27 (quarter ended June 30, 2026).
• Other matters as may be considered necessary with the chair's permission.

Other Notes

• Trading window closure periods not specified.

Postal ballot corrigendum and comment window

• Bal Pharma provides 48-hour comment window on Corrigendum to Postal Ballot Notice.
• Comments/observations/objections to Corrigendum modifications may be sent to investors@balpharma.com.
• Scrutinizer's email: parameshwar@vjkt.in for submissions.
• Remote e-voting remains open until 5:00 PM IST on Saturday, August 08, 2026.
• Existing voters may revise their votes as per Corrigendum Point No. 10.

XBRL alignment update

• Board-approved standalone and consolidated results unchanged.
• Earlier XBRL variations were due to filing utility and rounding.
• Refiled XBRL results now align with PDF figures.
• No change to the approved financial results.

Auditor declarations and governance

• Auditors SSJNB & Co issued unmodified opinion on results.
• Shreepada M L appointed Company Secretary and Compliance Officer.
• Internal auditors Murugesh & Co. appointed; Cost auditors G.N.V. & Associates appointed.

Dividend and capital actions

• Dividend of Re 1.20 per share (12%) recommended, subject to AGM.
• Approved preferential issue of 10 lakh warrants to promoters.
• Approved grant of 500,000 ESOPs under ESOP Plan-2025.
• Warrants to promoters to be approved via postal ballot.

Dematerialisation/Rematerialisation status

• Dematerialisation/rematerialisation details furnished to all stock exchanges within the prescribed time.
• Physical certificates received for dematerialisation mutilated and cancelled after verification; depository registered owner substituted within 15 days.
• Securities dematerialised/rematerialised have been listed on the relevant stock exchanges.

Resolution overview

• Item 1 (Special): approve preferential issue of 10,00,000 warrants to promoter at Rs 81 each.
• Warrants convertible into equity shares within 18 months.
• Total issue size Rs 8.10 crore.
• Upfront payment 25% at allotment; remaining 75% on conversion.
• Counterparty: promoter Shailesh Siroya; related-party transaction.
• Cut-off date for eligibility: 3 July 2026.
• Relevant date for price determination: 09 July 2026.
• Potential dilution for existing shareholders upon warrant exercise.
• Results announced by Aug 11, 2026 at registered office and exchanges.